Cellectar Ebit Per Revenue vs Capex To Revenue Analysis
CLRB Stock | USD 0.26 0.05 14.84% |
Cellectar Biosciences financial indicator trend analysis is way more than just evaluating Cellectar Biosciences prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Cellectar Biosciences is a good investment. Please check the relationship between Cellectar Biosciences Ebit Per Revenue and its Capex To Revenue accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cellectar Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Cellectar Stock refer to our How to Trade Cellectar Stock guide.
Ebit Per Revenue vs Capex To Revenue
Ebit Per Revenue vs Capex To Revenue Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Cellectar Biosciences Ebit Per Revenue account and Capex To Revenue. At this time, the significance of the direction appears to have pay attention.
The correlation between Cellectar Biosciences' Ebit Per Revenue and Capex To Revenue is -0.98. Overlapping area represents the amount of variation of Ebit Per Revenue that can explain the historical movement of Capex To Revenue in the same time period over historical financial statements of Cellectar Biosciences, assuming nothing else is changed. The correlation between historical values of Cellectar Biosciences' Ebit Per Revenue and Capex To Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Ebit Per Revenue of Cellectar Biosciences are associated (or correlated) with its Capex To Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capex To Revenue has no effect on the direction of Ebit Per Revenue i.e., Cellectar Biosciences' Ebit Per Revenue and Capex To Revenue go up and down completely randomly.
Correlation Coefficient | -0.98 |
Relationship Direction | Negative |
Relationship Strength | Significant |
Ebit Per Revenue
Capex To Revenue
The ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets.Most indicators from Cellectar Biosciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Cellectar Biosciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cellectar Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Cellectar Stock refer to our How to Trade Cellectar Stock guide.At present, Cellectar Biosciences' Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Sales General And Administrative To Revenue is expected to grow to 70.48, whereas Tax Provision is forecasted to decline to (56.7 K).
2021 | 2022 | 2023 | 2024 (projected) | Net Interest Income | 2.3K | 152.5K | 395.4K | 415.1K | Interest Income | 2.3K | 152.5K | 395.4K | 649.7K |
Cellectar Biosciences fundamental ratios Correlations
Click cells to compare fundamentals
Cellectar Biosciences Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Cellectar Biosciences fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 12.3M | 58.7M | 37.2M | 21.6M | 12.1M | 16.0M | |
Other Current Liab | (127.0) | 2.0M | 2.3M | 2.9M | 7.3M | 7.6M | |
Total Current Liabilities | 2.8M | 3.6M | 4.0M | 5.5M | 12.9M | 13.6M | |
Total Stockholder Equity | 9.1M | 54.8M | 33.0M | 15.5M | (1.4M) | (1.3M) | |
Property Plant And Equipment Net | 783.9K | 638.3K | 549.1K | 979.0K | 1.6M | 1.1M | |
Net Debt | (10.1M) | (56.7M) | (35.4M) | (19.3M) | (9.0M) | (9.5M) | |
Retained Earnings | (111.7M) | (126.8M) | (150.9M) | (179.5M) | (217.5M) | (206.6M) | |
Accounts Payable | 1.3M | 1.4M | 1.4M | 2.6M | 5.6M | 5.9M | |
Cash | 10.6M | 57.2M | 35.7M | 19.9M | 9.6M | 13.3M | |
Non Current Assets Total | 865.1K | 719.6K | 630.3K | 1.1M | 1.6M | 2.0M | |
Cash And Short Term Investments | 10.6M | 57.2M | 35.7M | 19.9M | 9.6M | 13.3M | |
Common Stock Total Equity | 167.0 | 47.0 | 94.0 | 454.0 | 408.6 | 448.7 | |
Common Stock Shares Outstanding | 767.5K | 2.0M | 5.6M | 7.1M | 12.2M | 12.8M | |
Liabilities And Stockholders Equity | 12.3M | 58.7M | 37.2M | 21.6M | 12.1M | 16.0M | |
Other Current Assets | 771.0K | 1.5M | 1.7M | 663.2K | 888.2K | 785.0K | |
Other Stockholder Equity | 119.6M | 161.5M | 182.6M | 193.6M | 211.4M | 222.0M | |
Total Liab | 3.2M | 3.9M | 4.2M | 6.1M | 13.4M | 14.1M | |
Property Plant And Equipment Gross | 783.9K | 356.0K | 549.1K | 979.0K | 2.5M | 2.6M | |
Total Current Assets | 11.4M | 57.9M | 36.6M | 20.5M | 10.5M | 14.0M | |
Accumulated Other Comprehensive Income | (5.8M) | (181.2K) | (309.4K) | (1.4M) | (1.6M) | (1.7M) | |
Common Stock | 47.0 | 94.0 | 454.0 | 611.0 | 207.0 | 196.65 | |
Non Current Liabilities Total | 421.6K | 301.7K | 166.3K | 553.0K | 494.0K | 469.3K | |
Current Deferred Revenue | 965.1K | 1.4M | 2.0M | 2.4M | 2.8M | 2.9M | |
Short Term Debt | 105.9K | 119.9K | 270.9K | 101.7K | 59.0K | 56.0K | |
Short Long Term Debt Total | 527.5K | 421.6K | 301.7K | 603.8K | 553.0K | 487.8K | |
Property Plant Equipment | 435.1K | 356.0K | 549.1K | 979.0K | 881.1K | 1.2M | |
Retained Earnings Total Equity | (84.3M) | (97.6M) | (111.7M) | (126.8M) | (114.1M) | (108.4M) | |
Preferred Stock Total Equity | 995.8K | 2.5M | 1.1M | 20.0M | 23.0M | 24.2M | |
Net Tangible Assets | 7.9M | 34.8M | 31.7M | 14.1M | 16.2M | 13.6M | |
Capital Surpluse | 94.1M | 108.3M | 119.6M | 161.5M | 185.8M | 103.4M | |
Capital Lease Obligations | 527.5K | 421.6K | 301.7K | 603.8K | 553.0K | 580.6K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Cellectar Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cellectar Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cellectar Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cellectar Biosciences Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cellectar Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Cellectar Stock refer to our How to Trade Cellectar Stock guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cellectar Biosciences. If investors know Cellectar will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cellectar Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.41) | Return On Assets (1.66) | Return On Equity (7.97) |
The market value of Cellectar Biosciences is measured differently than its book value, which is the value of Cellectar that is recorded on the company's balance sheet. Investors also form their own opinion of Cellectar Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Cellectar Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cellectar Biosciences' market value can be influenced by many factors that don't directly affect Cellectar Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cellectar Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cellectar Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cellectar Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.